Cure My Disease

Don't miss your cure!

 Log in / Sign up

PAH drug switch under the microscope: will patients benefit?

NCT ID NCT07013149

Recruiting now Knowledge-focused Sponsor: University of Sao Paulo General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This study looks at what happens when people with pulmonary arterial hypertension (PAH) switch from one medication (ambrisentan) to another (bosentan). Researchers will track 121 adults to see if their risk level, symptoms, and side effects change after the switch. The goal is to provide real-world data to help doctors make better treatment decisions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic thromboembolic pulmonary hypertension pulmonary arterial hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PULMONARY ARTERIAL HYPERTENSION PULMONARY ARTERIAL HYPERTENSION (PAH) PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1 PH)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • InCor - FMUSP

    RECRUITING

    São Paulo, São Paulo, Brazil

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.